Explaining the unexpected: Insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel

E. Magnus Ohman; Matthew T. Roe

doi:10.1160/TH11-03-0159

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2011; 105(05): 763-765
DOI: 10.1160/TH11-03-0159

Current Controversies

Schattauer GmbH

Explaining the unexpected: Insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel

E. Magnus Ohman

¹Duke Clinical Research Institute and Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA

,

Matthew T. Roe

¹Duke Clinical Research Institute and Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA

References
1 Serebruany VL. Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
2 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
3 The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
4 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
5 Bhatt DL, Fox KAA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
6 Steinhubl SR, Berger PB, Mann JT III. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. J Am Med Assoc 2002; 288: 2411-2420.
7 ISIS-2 (second international study of infarct survival) collaborative group.. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-360.
8 Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at – but don‘t believe them!. Curr Control Trials Cardiovasc Med 2000; 1: 25-27.
9 Yusuf S, Wittes J, Probstfield J. et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 1991; 266: 93-98.
10 The PURSUIT Trial Investigators.. Inhibition of platelet glycoprotein IIb/IIIa with etifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-443.
11 Akkerhuis KM, Deckers JW, Boersma E. et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Eur Heart J 2000; 21: 371-381.
12 Ruff CT, Giugliano RP, Antman EM. et al. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2010 epub ahead of print.
13 Bhatt DL, Flather MD, Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
14 Stone GW. Ticagrelor in ACS: redefining a new standard of care?. The Lancet 2010; 375: 263-265.
15 Mehran R, Pocock SJ, Stone GW. et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.